Jianhua Zhan

Jianhua Zhan

Auto-generated profile, based on publicly available information

Jianhua Zhan

Sun Yat-sen University Cancer Center 3 Guangzhou, guangdong

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2026 in Cancer Discovery
Verified
Journal Article
Closed access
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
While epidermal growth factor receptor (EGFR) fusions in non-small cell lung cancer (NSCLC) typically show sensitivity to tyrosine kinase inhibitors (TKIs), we identified an EGFR-SHC1 fusion subtype that exhibits intrinsic resistance to EGFR-TKI monotherapy through a dual activation mechanism in the preclinical and clinical setting. EGFR-SHC1 fusion protein comprises of N-terminal EGFR and C-terminal SHC1. We demonstrated that EGFR-SHC1 simultaneously activates the EGFR kinase domain (KD) and SRC-mediated phosphorylation of the SHC1 fusion partner, thereby driving ERK/AKT pathway activation and tumorigenesis independent of KD inhibition. Structural modeling coupled with domain-specific mutagenesis revealed that SHC1 phosphorylation establishes a kinase-independent bypass mechanism. Notably, dual-targeted inhibition using afatinib (EGFR-TKI) in combination with dasatinib (SRC-TKI) induced marked tumor regression in a TKI-refractory NSCLC patient with EGFR-SHC1. This study illustrates a cooperative oncogenesis between kinase and scaffold protein in fusions, providing a clinically actionable strategy for overcoming TKI resistance in patients with these oncogenic fusions.

3 August 2026
Verified
Other
Open access
PDF file
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
Supplementary Table S2 shows that individual clinicopathologic data have been reported in NSCLC patients with EGFR-fusions that were treated with EGFR-TKIs.

3 August 2026
Verified
Other
Open access
PDF file
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
Supplementary Figure S1 shows the identification and validation of the EGFR-SHC1 fusion in NSCLC patients, including RT-PCR and Sanger sequencing confirmation, as well as the oncogenic potential of EGFR-SHC1 demonstrated through immunoblotting, flow cytometry, soft agar colony formation, and IL-3-independent proliferation assays in transfected Ba/F3 and NIH3T3 cells. It also presents structural modeling of EGFR-SHC1 binding to three EGFR-TKIs and the corresponding binding energy calculations.

3 August 2026
Verified
Other
Open access
PDF file
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
Supplementary Figure S3 shows that both the N-terminal EGFR kinase domain and the C-terminal SHC1 phosphorylation sites contribute to the oncogenic properties of EGFR-SHC1, including analyses of SHC1 phosphorylation in response to EGF stimulation, TKI sensitivity in Ba/F3 cells, and functional assessments via soft agar colony formation and IL-3-independent proliferation assays using various EGFR-SHC1 mutants. It also includes immunoblotting validation of protein expression and downstream signaling in cells expressing EGFR-RAD51 and EGFR-SHC1 variants.

3 August 2026
Verified
Other
Open access
PDF file
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
Supplementary Table S3 shows that oligonucleotides used in this study.

3 August 2026
Verified
Other
Open access
PDF file
JZJiani Zheng
Jiani Zheng
SZShen Zhao
Shen Zhao
JZJianhua Zhan
Jianhua Zhan
WZWeitao Zhuang
Weitao Zhuang
MCMaojian Chen
Maojian Chen
JLJing Li
Jing Li
Supplementary Figure S2 shows that inactivation of the N-terminal EGFR kinase domain only partially abrogates the tumorigenicity of EGFR-SHC1, as demonstrated by soft agar colony formation assays. It also presents dose-response curves comparing the sensitivity of EGFR-RAD51 and EGFR-SHC1 to three EGFR-TKIs, along with immunoblotting analyses of downstream signaling inhibition following TKI treatment.